Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Final FDA flu vaccine guidances

Executive Summary

FDA issues final guidances to outline the regulatory pathways for development and approval of seasonal and pandemic influenza vaccines May 31. Both guidances recommend use of novel adjuvants and cell culture and recombinant manufacturing technologies. Guidelines also allow use of surrogate endpoints such as immune response to support accelerated approval (1"The Pink Sheet" March 13, 2006, p. 26)...

You may also be interested in...

Sixth flu vaccine approved

Accelerated approval of CSL Limited's Afluria for protection against flu virus types A and B in adults marks sixth seasonal influenza vaccine approved by FDA, agency says Sept. 28. CDC estimates a record 132 million vaccine doses will be available for 2007-2008 season (1"The Pink Sheet" Aug. 27, 2007, In Brief)...

Accelerated Approval Gives Wings To Pandemic Flu Vaccine Development

FDA has unveiled a strategy for preventing influenza vaccine shortages and getting a jump on flu pandemics by using surrogate endpoints to accelerate approval of new vaccines

Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off

Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts